ONCODESIGN PM
Identification
Listing sponsor / Agent
Bryan Garnier & Co
Symbol
MLOPM
ISIN code
FR001400CM63
Code LEI
969500ZDX1IY47LDL876
Exchange / Market
Euronext Access+
Trading location
Paris
ICB
20103010 Biotechnology
Website address
https://opm.oncodesign.com
Operation
IPO date
Wed 05/10/2022
IPO type
Direct listing
Company profile
Oncodesign Precision Medicine is a biopharmaceutical company specializing in precision medicine to treat resistant and metastatic cancers. Oncodesign Precision Medicine 's innovative technologies are OncoSNIPER for the selection of therapeutic targets using artificial intelligence, Nanocyclix® for the design and selection of macrocyclic small molecule kinase inhibitors and Promethe for the design and selection of radiolabeled biological molecules for systemic radiotherapy.
Source:
Cofisem
-
Last Update:
16 May 2025
Key Executives
| Chairman and Chief Executive Officer | Philippe Genne | ||||
| Deputy CEO | Jan Hoflack | ||||
| Chief Scientific Officer | Jan Hoflack | ||||
| Deputy CEO | Karine Lignel | ||||
| Chief Operating Officer | Karine Lignel | ||||
| Source: Cofisem - Last Update: 16 May 2025 | |||||
Key figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 207.040 | 1.072.170 | 7.980.831 | 3.830.987 | 4.410.132 |
| Consumed purchases | 6.512.038 | 7.997.080 | 7.561.530 | 5.923.533 | 9.246.469 |
| Labour costs | 2.591.760 | 3.311.741 | 2.082.044 | 1.513.223 | 1.346.556 |
| Operating profit | -7.807.082 | -9.943.732 | -1.610.088 | -3.725.900 | -6.166.375 |
| Income tax | -1.100.966 | -1.763.150 | -1.491.414 | -1.134.898 | -1.540.781 |
| Net income | -7.209.619 | -8.090.675 | -231.181 | -2.944.338 | -153.826 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - unit | EUR - unit | EUR - unit | EUR - unit | EUR - unit |
| Account Standards | French_GAAP | French_GAAP | French_GAAP | French_GAAP | French_GAAP |
| Source: Cofisem - Last Update: 16 May 2025 | |||||